Today: October 23, 2016, 1:34 am

Global psoriasis market: Almost 41 million cases by 2022
EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 - a new market research report on 2014-03-03 05:54:01
Psoriasis has a complex collection of risk factors, such as genetics, lifestyle choices, and exposure to certain environmental conditions. There were approximately 36.5 million prevalent cases of psoriasis across all the US, France, Germany, Italy, Spain, UK, Japan, China, and India in 2012. By 2022, epidemiologists forecast that this figure will reach approximately 40.93 million prevalent cases, following a 12.1% increase based on projected population growth - prevalence proportions are expected to remain constant.

Psoriasis is an immune-mediated chronic dermatological disorder characterized by redness and irritation. The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world. The age-standardized prevalence of psoriasis varies among different countries, from as low as 0.03% in Japan to as high as 1.84% in Germany. These regional differences may be attributable to variations in environmental factors such as the weather, as well as genetic factors, and differences in data collection across different countries.

The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy, and similar regional differences have been reported in Spain, with psoriasis more common among the residents of central Spain, who experience colder and drier weather than individuals in the northern and southern regions.

Ethnicity may also play a part - studies have shown that Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.

Psoriasis is an autoimmune disorder, so family history plays an important role in the development of the disease. Approximately 40% of psoriasis patients have first-degree relatives with the disease. Since psoriasis is categorized as an immune-mediated inflammatory disorder (IMFD), sufferers are also at an increased risk of developing other, more severe IMFDs, such as rheumatoid arthritis and Crohns disease.

Psoriasis patients are also at risk of developing psoriatic arthritis, which is a progressive, deforming, and debilitating disease and the most common comorbidity associated with psoriasis. However, lifestyle choices, and certain diseases and medications can affect the condition. Smoking increases the risk of developing psoriasis, and increases the severity of the disease. In addition, it has been noted that psoriasis is a common disease among obese patients, although the relationship between the two disorders remains unclear. Obesity also predisposes individuals to inverse or flexural psoriasis, which occurs in the folds of the skin. Various medications, such as lithium, anti-malarial agents, betablocking agents, and non-steroidal anti-inflammatory drugs (NSAIDs), are also considered as possible risk factors, though there is insubstantial evidence to prove this as yet.

The disease can be controlled with medication, but a cure has not yet been found. Psoriasis is often associated with unsightly lesions, scales, and inflammation, which can affect an individuals self-esteem, leading nearly half of all psoriasis patients to report elevated stress levels, depression, and thoughts of suicide. Stress can trigger pathological processes, exacerbating many dermatological conditions, particularly psoriasis. Psoriasis patients suffering from these anxieties can also limit their social interactions and abuse alcohol and tobacco, further worsening their condition.

Report Scope

- The Psoriasis EpiCast Report provides an overview of the risk factors and global trends of psoriasis in the nine major markets (the US, France, Germany, Italy, Spain, the UK, Japan, China, and India).
- It includes a 10-year epidemiology forecast of the prevalent cases of psoriasis segmented by sex and age (by five-year increments, beginning at age 15 years and ending at =85 years) in the 9MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global psoriasis market.
- Quantify patient populations in the global psoriasis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for psoriasis therapeutics in each of the markets covered.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 846 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.